Cullinan Oncology (CGEM)

• Market cap: $675M
• 1 day: 5.94%
• 5 days: -1.28%
• 1 month: -7.79%
• 3 months: -36.09%
• 6 months: -33.75%
• Year to date: 9.54%
• 1 year: 32.72%
• 5 years: -61.22%
• 10 years: -61.22%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Employees: 85

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

431% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $2.1M

136% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 28

17% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

1% more funds holding

Funds holding: 135 [Q2] → 137 (+2) [Q3]

1.47% more ownership

Funds ownership: 110.64% [Q2] → 112.12% (+1.47%) [Q3]

2% less capital invested

Capital invested by funds: $1.11B [Q2] → $1.09B (-$25M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 141% upside
• Avg. target: $29 150% upside
• High target: $30 159% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

UBS David Dai 18% 1-year accuracy 2 / 11 met price target	159% upside $30	Buy Initiated	24 Oct 2024
HC Wainwright & Co. Edward White 26% 1-year accuracy 37 / 142 met price target	141% upside $28	Buy Reiterated	16 Oct 2024